Home   >  

Classified by application

All Products

Signaling Pathways

Research Areas

Nature products






Raw Materials


Chemical Structure Cat. No. Product Name CAS No.
TAS-117 Chemical Structure
BCP41128 TAS-117 1402602-94-1
TAS-117 is a PKB/Akt inhibitor potentially for the treatment of solid tumors.
PF-06679142 Chemical Structure
BCP40393 PF-06679142 1467059-66-0
PF-06679142 is a potent AMPK activator.
SRX3207 Chemical Structure
BCP40266 SRX3207 2254693-15-5
SRX3207 is an orally active dual inhibitor of Syk-PI3K with IC50 of 39.9 nM, 31200 nM, 3070 nM, 3070 nM, 244 nM, 388 nM, 9790 nM for Syk, Zap70, BRD41, BRD42, PI3K alpha, PI3K delta, PI3K gamma, respectively.
IPI-3063 Chemical Structure
BCP39855 IPI-3063 1425043-73-7
IPI-3063 is a potent and selective phosphoinoside-3-kinase (PI3K) p110δ inhibitor. IPI-3063 was shown to inhibit mouse B cell proliferation, survival, and plasmablast differentiation, and also inhibit human B cell proliferation in vitro.
NV-5138 Chemical Structure
BCP39080 NV-5138 2095886-80-7
NV-5138, a leucine analog, is the first selective and orally active brain mTORC1 activator, binding to Sestrin2.
Nemiralisib Chemical Structure
BCP38658 Nemiralisib 1254036-71-9
Nemiralisib, also known as GSK2269557, is a highly potent and selective inhaled PI3Kδ inhibitor for the treatment of COPD.
KY19382 Chemical Structure
BCP38332 KY19382 2226664-93-1
KY19382 is a potent and orally active dual inhibitor of CXXC5-DVL and GSK3β, with IC50s of 19 and 10 nM, respectively.
AZD6738 chiral mixtures Chemical Structure
BCP38320 AZD6738 chiral mixtures 1352280-97-7
AZD6738 is an orally active, and selective ATR kinase inhibitor with IC50 of 1 nM.
(S)-Ceralasertib Chemical Structure
BCP38319 (S)-Ceralasertib 1352226-87-9
(S)-Ceralasertib is a potent and selective sulfoximine morpholinopyrimidine ATR inhibitor with excellent preclinical physicochemical and pharmacokinetic (PK) characteristics.
MT 63-78 Chemical Structure
BCP38015 MT 63-78 1179347-65-9
MT 63-78 is a direct activator of AMPK, and an inhibitor of prostate cancer growth by blocking lipogenesis.
123下一頁末頁共 342 條記錄 1 / 35 頁